Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant humanized anti-VEGF monoclonal antibody
- Development stage
- Phase 1
- Lead developer
- Shanghai Kangdai Biopharmaceutical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
recombinant humanized anti-VEGF monoclonal antibody is a biosimilar of the anti-VEGF monoclonal antibody bevacizumab (Avastin), developed by Shanghai Kangdai Biopharmaceutical Technology. It is designed to target vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis, growth, and metastasis. The drug has been evaluated in a Phase 1 clinical trial in China to establish pharmacokinetic similarity, safety, tolerability, and immunogenicity compared to reference bevacizumab in healthy adult males, with therapeutic development focused on metastatic colorectal cancer and advanced or metastatic non-small cell lung cancer.
- Other names
- bevacizumab biosimilar (Shanghai Kangdai)recombinant humanized anti-VEGF monoclonal antibody injection
02
Targets
VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on recombinant humanized anti-VEGF monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant humanized anti-VEGF monoclonal antibody.